These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23323523)

  • 1. Improvement of HBsAg gene-modified dendritic cell-based vaccine efficacy by optimizing immunization method or the application of β-glucosylceramide.
    Long J; Zhou B; Li H; Dai Q; Zhang B; Xing S; Zeng Z; Chen W; Yang J
    Immunol Invest; 2013; 42(2):137-55. PubMed ID: 23323523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
    Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
    Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immune response of HBsAg gene-modified dendritic cell-based vaccine in HepG2. 2. 15 hepatocellular carcinoma cells].
    Yang JY; Liu WC; Cao DY; Si XM; Teng ZH
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):728-32. PubMed ID: 18396682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Feasibility of using hepatitis B virus surface antigen as target antigen in immunogen therapy against cancer].
    Qiu S; Ye S; Tang Z; Qian S; Li L
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):253-6. PubMed ID: 11953174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
    Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG
    Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models.
    Hayashi T; Nakao K; Nagayama Y; Saitoh O; Ichikawa T; Ishikawa H; Hamasaki K; Eguchi K; Ishii N
    Int J Oncol; 2005 May; 26(5):1313-9. PubMed ID: 15809723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
    Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
    Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.
    Qiu SJ; Lu L; Qiao C; Wang L; Wang Z; Xiao X; Qian S; Fung JJ; Ye SL; Bonham CA
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):429-38. PubMed ID: 15818505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
    You J; Wang CL; Hao XS
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
    Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
    Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg.
    Huang Y; Chen Z; Jia H; Wu W; Zhong S; Zhou C
    Clin Immunol; 2006 Jun; 119(3):280-90. PubMed ID: 16531121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
    Ren W; Strube R; Zhang X; Chen SY; Huang XF
    Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.
    Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
    Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.